TY - JOUR
T1 - Liquid biopsy
T2 - a step closer to transform diagnosis, prognosis and future of cancer treatments
AU - Lone, Saife N.
AU - Nisar, Sabah
AU - Masoodi, Tariq
AU - Singh, Mayank
AU - Rizwan, Arshi
AU - Hashem, Sheema
AU - El-Rifai, Wael
AU - Bedognetti, Davide
AU - Batra, Surinder K.
AU - Haris, Mohammad
AU - Bhat, Ajaz A.
AU - Macha, Muzafar A.
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. Liquid biopsies consist of isolating tumor-derived entities like circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc., present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data contained within them. Methods for isolation and analysis of liquid biopsies have rapidly evolved over the past few years as described in the review, thus providing greater details about tumor characteristics such as tumor progression, tumor staging, heterogeneity, gene mutations, and clonal evolution, etc. Liquid biopsies from cancer patients have opened up newer avenues in detection and continuous monitoring, treatment based on precision medicine, and screening of markers for therapeutic resistance. Though the technology of liquid biopsies is still evolving, its non-invasive nature promises to open new eras in clinical oncology. The purpose of this review is to provide an overview of the current methodologies involved in liquid biopsies and their application in isolating tumor markers for detection, prognosis, and monitoring cancer treatment outcomes.
AB - Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. Liquid biopsies consist of isolating tumor-derived entities like circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc., present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data contained within them. Methods for isolation and analysis of liquid biopsies have rapidly evolved over the past few years as described in the review, thus providing greater details about tumor characteristics such as tumor progression, tumor staging, heterogeneity, gene mutations, and clonal evolution, etc. Liquid biopsies from cancer patients have opened up newer avenues in detection and continuous monitoring, treatment based on precision medicine, and screening of markers for therapeutic resistance. Though the technology of liquid biopsies is still evolving, its non-invasive nature promises to open new eras in clinical oncology. The purpose of this review is to provide an overview of the current methodologies involved in liquid biopsies and their application in isolating tumor markers for detection, prognosis, and monitoring cancer treatment outcomes.
KW - Cancer
KW - Circulating tumor DNA
KW - Circulating tumor cells
KW - Liquid biopsy
KW - Non-invasive tumor detection
KW - Precision medicine Cancer diagnosis
KW - Tumor extracellular vesicles
UR - http://www.scopus.com/inward/record.url?scp=85126668076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126668076&partnerID=8YFLogxK
U2 - 10.1186/s12943-022-01543-7
DO - 10.1186/s12943-022-01543-7
M3 - Review article
C2 - 35303879
AN - SCOPUS:85126668076
SN - 1476-4598
VL - 21
JO - Molecular cancer
JF - Molecular cancer
IS - 1
M1 - 79
ER -